Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2021 Jan 30

PMID 33514009

Citations 6

Authors

Marika Ruponen

Konsta Kettunen

Monica Santiago Pires

Riikka Laitinen

Affiliations

Soon will be listed here.

Abstract

In this study, the amino acid arginine (ARG) and P-glycoprotein (P-gp) inhibitors verapamil hydrochloride (VER), piperine (PIP) and quercetin (QRT) were used as co-formers for co-amorphous mixtures of a Biopharmaceutics classification system (BCS) class IV drug, furosemide (FUR). FUR mixtures with VER, PIP and QRT were prepared by solvent evaporation, and mixtures with ARG were prepared by spray drying in 1:1 and 1:2 molar ratios. The solid-state properties of the mixtures were characterized with X-ray powder diffraction (XRPD), Fourier-transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) in stability studies under different storage conditions. Simultaneous dissolution/permeation studies were conducted in side-by-side diffusion cells with a PAMPA (parallel artificial membrane permeability assay) membrane as a permeation barrier. It was observed with XRPD that ARG, VER and PIP formed co-amorphous mixtures with FUR at both molar ratios. DSC and FTIR revealed single glass transition values for the mixtures (except for FUR:VER 1:2), with the formation of intermolecular interactions between the components, especially salt formation between FUR and ARG. The co-amorphous mixtures were found to be stable for at least two months under an elevated temperature/humidity, except FUR:ARG 1:2, which was sensitive to humidity. The dissolution/permeation studies showed that only the co-amorphous FUR:ARG mixtures were able to enhance both the dissolution and permeation of FUR. Thus, it is concluded that formulating co-amorphous salts with ARG may be a promising option for poorly soluble/permeable FUR.

Citing Articles

The usefulness of infrared spectroscopy and X-ray powder diffraction in the analysis of falsified, illegal, and medicinal products.

Mocarska A, Piorunska K, Maurin J, Blazewicz A Front Chem. 2025; 13:1536209.

PMID: 40046017 PMC: 11879982. DOI: 10.3389/fchem.2025.1536209.

Coformer-Dependent Physical Stability in a Series of Naringenin-Based Coamorphous Materials with Caffeine, Theophylline, and Theobromine.

Jadhav S, Bahl D, Stevens L Pharm Res. 2023; 40(12):2847-2858.

PMID: 37505378 DOI: 10.1007/s11095-023-03562-5.

Data-Driven Prediction of the Formation of Co-Amorphous Systems.

Fink E, Brunsteiner M, Mitsche S, Schrottner H, Paudel A, Zellnitz-Neugebauer S Pharmaceutics. 2023; 15(2).

PMID: 36839668 PMC: 9968185. DOI: 10.3390/pharmaceutics15020347.

A Review of Coformer Utilization in Multicomponent Crystal Formation.

Wathoni N, Sari W, Elamin K, Mohammed A, Suharyani I Molecules. 2022; 27(24).

PMID: 36557827 PMC: 9786674. DOI: 10.3390/molecules27248693.

Amorphous and Co-Amorphous Olanzapine Stability in Formulations Intended for Wet Granulation and Pelletization.

da Costa N, Daniels R, Fernandes A, Pinto J Int J Mol Sci. 2022; 23(18).

PMID: 36142179 PMC: 9499418. DOI: 10.3390/ijms231810234.

References

Li Y, Wong H, Shuhendler A, Rauth A, Wu X . Molecular interactions, internal structure and drug release kinetics of rationally developed polymer-lipid hybrid nanoparticles. J Control Release. 2008; 128(1):60-70. DOI: 10.1016/j.jconrel.2008.02.014. View

Ghebremeskel A, Vemavarapu C, Lodaya M . Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: selection of polymer-surfactant combinations using solubility parameters and testing the processability. Int J Pharm. 2006; 328(2):119-29. DOI: 10.1016/j.ijpharm.2006.08.010. View

Lobmann K, Strachan C, Grohganz H, Rades T, Korhonen O, Laitinen R . Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions. Eur J Pharm Biopharm. 2012; 81(1):159-69. DOI: 10.1016/j.ejpb.2012.02.004. View

Gallignani M, Rondon R, Ovalles J, Brunetto M . Transmission FTIR derivative spectroscopy for estimation of furosemide in raw material and tablet dosage form. Acta Pharm Sin B. 2015; 4(5):376-83. PMC: 4629100. DOI: 10.1016/j.apsb.2014.06.013. View

Korhonen O, Pajula K, Laitinen R . Rational excipient selection for co-amorphous formulations. Expert Opin Drug Deliv. 2016; 14(4):551-569. DOI: 10.1080/17425247.2016.1198770. View

Ojarinta R, Lerminiaux L, Laitinen R . Spray drying of poorly soluble drugs from aqueous arginine solution. Int J Pharm. 2017; 532(1):289-298. DOI: 10.1016/j.ijpharm.2017.09.015. View

Kaminska E, Adrjanowicz K, Kaminski K, Wlodarczyk P, Hawelek L, Kolodziejczyk K . A new way of stabilization of furosemide upon cryogenic grinding by using acylated saccharides matrices. The role of hydrogen bonds in decomposition mechanism. Mol Pharm. 2013; 10(5):1824-35. DOI: 10.1021/mp300606p. View

Beyers H, Malan S, van der Watt J, de Villiers M . Structure-solubility relationship and thermal decomposition of furosemide. Drug Dev Ind Pharm. 2000; 26(10):1077-83. DOI: 10.1081/ddc-100100271. View

Ghadi R, Dand N . BCS class IV drugs: Highly notorious candidates for formulation development. J Control Release. 2017; 248:71-95. DOI: 10.1016/j.jconrel.2017.01.014. View

10.

Miyaji Y, Fujii Y, Takeyama S, Kawai Y, Kataoka M, Takahashi M . Advantage of the Dissolution/Permeation System for Estimating Oral Absorption of Drug Candidates in the Drug Discovery Stage. Mol Pharm. 2016; 13(5):1564-74. DOI: 10.1021/acs.molpharmaceut.6b00044. View

11.

Thenmozhi K, Yoo Y . Enhanced solubility of piperine using hydrophilic carrier-based potent solid dispersion systems. Drug Dev Ind Pharm. 2017; 43(9):1501-1509. DOI: 10.1080/03639045.2017.1321658. View

12.

Wang R, Han J, Jiang A, Huang R, Fu T, Wang L . Involvement of metabolism-permeability in enhancing the oral bioavailability of curcumin in excipient-free solid dispersions co-formed with piperine. Int J Pharm. 2019; 561:9-18. DOI: 10.1016/j.ijpharm.2019.02.027. View

13.

Volpe D . Variability in Caco-2 and MDCK cell-based intestinal permeability assays. J Pharm Sci. 2007; 97(2):712-25. DOI: 10.1002/jps.21010. View

14.

Lobmann K, Laitinen R, Grohganz H, Gordon K, Strachan C, Rades T . Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen. Mol Pharm. 2011; 8(5):1919-28. DOI: 10.1021/mp2002973. View

15.

Granero G, Longhi M, Mora M, Junginger H, Midha K, Shah V . Biowaiver monographs for immediate release solid oral dosage forms: furosemide. J Pharm Sci. 2009; 99(6):2544-56. DOI: 10.1002/jps.22030. View

16.

Nielsen L, Gordon S, Holm R, Selen A, Rades T, Mullertz A . Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats. Eur J Pharm Biopharm. 2013; 85(3 Pt B):942-51. DOI: 10.1016/j.ejpb.2013.09.002. View

17.

Beyer A, Grohganz H, Lobmann K, Rades T, Leopold C . Improvement of the physicochemical properties of Co-amorphous naproxen-indomethacin by naproxen-sodium. Int J Pharm. 2017; 526(1-2):88-94. DOI: 10.1016/j.ijpharm.2017.04.011. View

18.

Ruponen M, Visti M, Ojarinta R, Laitinen R . Permeability of glibenclamide through a PAMPA membrane: The effect of co-amorphization. Eur J Pharm Biopharm. 2018; 129:247-256. DOI: 10.1016/j.ejpb.2018.06.007. View

19.

Ajazuddin , Alexander A, Qureshi A, Kumari L, Vaishnav P, Sharma M . Role of herbal bioactives as a potential bioavailability enhancer for Active Pharmaceutical Ingredients. Fitoterapia. 2014; 97:1-14. DOI: 10.1016/j.fitote.2014.05.005. View

20.

Ruponen M, Rusanen H, Laitinen R . Dissolution and Permeability Properties of Co-Amorphous Formulations of Hydrochlorothiazide. J Pharm Sci. 2020; 109(7):2252-2261. DOI: 10.1016/j.xphs.2020.04.008. View